The Pyruvate Kinase Activator Etavopivat (FT-4202) Limits Pulmonary and Systemic Sequelae of Sepsis in a Mouse LPS Model
FT-4202 treatment significantly increased intra-RBC ATP and ATP export. We conclude that the PKRA FT-4202 protected against systemic and respiratory (capillary permeability and neutrophil influx) features of sepsis induced by LPS in mice. FT-4202 promoted RBC ATP generation and export ex vivo, which could contribute to the favorable effects in LPS-induced sepsis.
Authors
- Sylvie M. Guichard (ORCID: https://orcid.org/0000-0003-1143-2805)
- Apoorva Jagadish (ORCID: https://orcid.org/0000-0002-4281-1640)
- Marcus A. Carden (ORCID: https://orcid.org/0000-0003-3860-3619)
- T. McMahon (ORCID: https://orcid.org/0000-0002-3404-3223)
- Rodolfo Estupinan
- Ian J. Welsby (ORCID: https://orcid.org/0000-0002-2789-5612)
- Hongmei Zhu (ORCID: https://orcid.org/0000-0002-6935-8284)
- Desmond Wai Loon Chin
- Shein-Chung Chow
- Weijia Mai
- Lisheng Zhang (ORCID: https://orcid.org/0000-0002-9276-6454)
- Youwei Chen
Institutions
- Durham VA Health Care System (US)
- Novo Nordisk (United Kingdom) (GB)
- Duke University Health System (US)
Publication Details
- Journal
- American Journal of Physiology-Lung Cellular and Molecular Physiology
- Published
- 2026-04-13
- DOI
- https://doi.org/10.1152/ajplung.00389.2025
- Primary Topic
- Erythrocyte Function and Pathophysiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health